National Institute on Drug Abuse; Notice of Closed Meetings, 28673-28674 [2017-13078]
Download as PDF
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 120 / Friday, June 23, 2017 / Notices
encouraged to access the meeting Web
page to stay abreast of the most current
information regarding the meeting.
Request for Comments: NTP invites
written and oral public comments on
the draft monograph. The deadline for
submission of written comments is July
14, 2017, to enable review by the peer
review panel and NTP staff prior to the
meeting. Registration to provide oral
comments is by July 14, 2017, at https://
ntp.niehs.nih.gov/go/38853. Public
comments and any other
correspondence on the draft monograph
should be sent to the FOR FURTHER
INFORMATION CONTACT. Persons
submitting written comments should
include their name, affiliation, mailing
address, phone, email, and sponsoring
organization (if any). Written comments
received in response to this notice will
be posted on the NTP Web site, and the
submitter will be identified by name,
affiliation, and/or sponsoring
organization (if any). Guidelines for
public comments are at https://
ntp.niehs.nih.gov/ntp/about_ntp/
guidelines_public_comments_508.pdf.
Public comment at this meeting is
welcome, with time set aside for the
presentation of oral comments on the
draft monograph. In addition to inperson oral comments at the NIEHS,
public comments can be presented by
teleconference line. There will be 50
lines for this call; availability is on a
first-come, first-served basis. The lines
will be open from 8:30 a.m. until
adjournment at approximately 4:00 p.m.
EDT on July 24, 2017, although oral
comments will be received only during
the formal public comment periods
indicated on the preliminary agenda.
The access number for the
teleconference line will be provided to
registrants by email prior to the meeting.
Each organization is allowed one time
slot. At least 7 minutes will be allotted
to each time slot, and if time permits,
the allotment may be extended to 10
minutes at the discretion of the chair.
Persons wishing to make an oral
presentation are asked to register online
at https://ntp.niehs.nih.gov/go/38853 by
July 14, 2017, and indicate whether they
will present comments in-person or via
the teleconference line. If possible, oral
public commenters should send a copy
of their slides and/or statement or
talking points at that time. Written
statements can supplement and may
expand the oral presentation.
Registration for in-person oral
comments will also be available at the
meeting, although time allowed for
presentation by on-site registrants may
be less than that for registered speakers
and will be determined by the number
of speakers who register on-site.
VerDate Sep<11>2014
19:21 Jun 22, 2017
Jkt 241001
Background Information on the RoC:
Published biennially, each edition of the
RoC is cumulative and consists of
substances newly reviewed in addition
to those listed in previous editions. For
each listed substance, the RoC contains
a substance profile, which provides
information on cancer studies that
support the listing—including those in
humans, animals, and studies on
possible mechanisms of action—
information about potential sources of
exposure to humans, and current federal
regulations to limit exposures. The 14th
RoC, the latest edition, was published
on November 3, 2016 (available at
https://ntp.niehs.nih.gov/go/roc14).
Background Information on NTP Peer
Review Panels: NTP panels are
technical, scientific advisory bodies
established on an ‘‘as needed’’ basis to
provide independent scientific peer
review and advise the NTP on agents of
public health concern, new/revised
toxicological test methods, or other
issues. These panels help ensure
transparent, unbiased, and scientifically
rigorous input to the program for its use
in making credible decisions about
human hazard, setting research and
testing priorities, and providing
information to regulatory agencies about
alternative methods for toxicity
screening. NTP welcomes nominations
of scientific experts for upcoming
panels. Scientists interested in serving
on an NTP panel should provide current
curriculum vitae to the FOR FURTHER
INFORMATION CONTACT (see above). The
authority for NTP panels is provided by
42 U.S.C. 217a; section 222 of the Public
Health Service (PHS) Act, as amended.
The panel is governed by the Federal
Advisory Committee Act, as amended (5
U.S.C. Appendix 2), which sets forth
standards for the formation and use of
advisory committees.
Dated: June 6, 2017.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2017–13159 Filed 6–22–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
28673
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Summer Research Education Experience
Programs (R25).
Date: June 30, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploratory Studies of Smoking Cessation
Interventions for People with Schizophrenia
(R21/R33; R33).
Date: July 12, 2017.
Time: 2:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Evaluating the NIDA Standardized Research
E-Cigarette in Risk Reduction and Related
Studies (U01).
Date: July 21, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: Courtyard by Marriott Chevy Chase,
5520 Wisconsin Avenue, Chevy Chase, MD
20815.
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
E:\FR\FM\23JNN1.SGM
23JNN1
28674
Federal Register / Vol. 82, No. 120 / Friday, June 23, 2017 / Notices
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Expanding Medication Assisted Treatment
for Opioid Use Disorders in the Context of
the SAMHSA Opioid STR Grants (R21/R33).
Date: July 25, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: June 19, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–13078 Filed 6–22–17; 8:45 am]
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room #3G41B, National Institutes
of Health/NIAID, 5601 Fishers Lane,
MSC9823, Bethesda, MD 20892–9823, (240)
669–5068, zhuqing.li@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; LIMITED COMPETITION:
CTOT–C MECHANISTIC ANCILLARY
STUDIES (U01).
Date: July 18, 2017.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room #3G41B, National Institutes
of Health/NIAID, 5601 Fishers Lane,
MSC9823, Bethesda, MD 20892–9823, (240)
669–5068, zhuqing.li@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 19, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–13077 Filed 6–22–17; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID CLINICAL TRIAL
PLANNING GRANT (R34).
Date: July 17, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
VerDate Sep<11>2014
19:21 Jun 22, 2017
Jkt 241001
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–6036–N–01]
Housing Trust Fund Federal Register;
Allocation Notice
Office of the Assistant
Secretary for Community Planning and
Development, HUD.
ACTION: Notice of Fiscal Year 2017
Funding Awards.
AGENCY:
The Housing and Economic
Recovery Act of 2008 (HERA)
established the Housing Trust Fund
(HTF) to be administered by HUD.
Pursuant to the Federal Housing
Enterprises Financial Security and
Soundness Act of 1992 (the Act), as
amended by HERA, Division A, eligible
HTF grantees are the 50 states, the
District of Columbia, the
Commonwealth of Puerto Rico,
American Samoa, Guam, the
Commonwealth of Northern Mariana
Islands, and the United States Virgin
Islands. In accordance with Section
1338(c)(4)(A) of the Act, this notice
announces the formula allocation
amount for each eligible HTF grantee.
SUMMARY:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Virginia Sardone, Director, Office of
Affordable Housing Programs, Room
7164, Department of Housing and Urban
Development, 451 Seventh Street SW.,
Washington, DC 20410–7000; telephone
(202) 708–2684. (This is not a toll-free
number.) A telecommunications device
for hearing- and speech-impaired
persons (TTY) is available at 800–877–
8339 (Federal Relay Service).
Section
1131 of HERA Division A amended the
Act to add a new section 1337 entitled
‘‘Affordable Housing Allocations’’ and a
new section 1338 entitled ‘‘Housing
Trust Fund.’’ HUD’s implementing
regulations are codified at 24 CFR part
93. Congress authorized the HTF with
the stated purpose of: (1) Increasing and
preserving the supply of rental housing
for extremely low-income families with
incomes between 0 and 30 percent of
area median income and very lowincome families with incomes between
30 and 50 percent of area median
income, including homeless families,
and (2) increasing homeownership for
extremely low-income and very lowincome families. Section 1337 of the Act
provides for the HTF (and other
programs) to be funded with an
affordable housing set-aside by Fannie
Mae and Freddie Mac. The total setaside amount is equal to 4.2 basis points
(.042 percent) of Fannie Mae and
Freddie Mac’s new mortgage purchases,
a portion of which is for the HTF.
Section 1338 of the Act directs HUD to
establish, through regulation, the
formula for distribution of amounts
made available for the HTF. The statute
specifies the factors to be used for the
formula and priority for certain factors.
The factors and methodology HUD uses
to allocate HTF funds among eligible
grantees are established in the HTF
regulation. The funding announced for
Fiscal Year 2017 through this notice is
$219,168,373.94. This amount includes
$12,702,747 of unobligated Fiscal Year
2016 HTF funds that will be reallocated
by formula, which are comprised of
$37,298 from American Samoa, Guam,
and the Commonwealth of Northern
Mariana Islands, three Insular Areas that
declined their Fiscal Year 2016
allocations and $12,665,449 of
Sequestered Fiscal Year 2016 funds.
HUD may add any amounts that may
become available to these FY 2017 HTF
allocation amounts. Appendix A to this
notice provides the names of the
grantees and the amounts of the awards.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\23JNN1.SGM
23JNN1
Agencies
[Federal Register Volume 82, Number 120 (Friday, June 23, 2017)]
[Notices]
[Pages 28673-28674]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-13078]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Summer Research Education Experience Programs (R25).
Date: June 30, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892,
301-827-5840, julia.berzhanskaya@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploratory Studies of Smoking Cessation
Interventions for People with Schizophrenia (R21/R33; R33).
Date: July 12, 2017.
Time: 2:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892,
301-827-5840, julia.berzhanskaya@nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Evaluating the NIDA Standardized Research E-
Cigarette in Risk Reduction and Related Studies (U01).
Date: July 21, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue,
Chevy Chase, MD 20815.
Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda,
[[Page 28674]]
MD 20892, 301-827-5840, julia.berzhanskaya@nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Expanding Medication Assisted Treatment for Opioid
Use Disorders in the Context of the SAMHSA Opioid STR Grants (R21/
R33).
Date: July 25, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,
hiromi.ono@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: June 19, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-13078 Filed 6-22-17; 8:45 am]
BILLING CODE 4140-01-P